Navigation Links
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
Date:12/10/2008

act with paliperidone. Please inform your healthcare professional of any medications or supplements that you are taking.

Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with paliperidone and similar medications. TD includes uncontrollable movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with the length of therapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped.

High blood sugar and diabetes have been reported with paliperidone and similar medications. If the person being treated has diabetes or risk factors such as being overweight or a family history of diabetes, blood sugar testing should be performed at the beginning and throughout treatment with paliperidone. Complications of diabetes can be serious and even life threatening. If signs of high blood sugar or diabetes develop, such as being thirsty all the time, going to the bathroom a lot, or feeling weak or hungry, contact your doctor.

Paliperidone and similar medications can raise the blood levels of a hormone known as prolactin, causing a condition known as hyperprolactinemia. Blood levels of prolactin remain elevated with continued use. Some side effects seen with these medications include the absence of a menstrual period; breasts producing milk; the development of breasts by males; and the inability to achieve an erection. The connection between prolactin levels and side effects is unknown.

People with narrowing or blockage of the gastrointestinal tract (esophagus, stomach or small or large intestine) should talk to their healthcare professional before taking paliperidone.

'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
6. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
7. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. SemBioSys begins phase I/II trial of insulin produced in plant seeds
10. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
11. OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... to German life sciences entrepreneurs with a proven ... biotechnology (collectively, the "Optionee"), an option to license ... technology (the "Technology"), including AEZS-120, the most advanced ... to enter a Phase 1 clinical trial. This ...
(Date:7/27/2015)... July 27, 2015  Amgen (NASDAQ: AMGN ) ... financial results on Thursday, July 30, 2015, after the ... be followed by a conference call with the investment ... from Amgen will be Robert A. Bradway , ... Amgen,s senior management team. Live audio of ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... Production of ... over the past few years in the EU. For instance, it surpassed the EUR ... EUR 92 million mark in 2010. Germany is a major producer, while Italy is ...
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® announced the addition ... will bring the world’s most efficient gas dissolution technology to all of Florida, ... both the industrial and municipal markets. With offices located in Sarasota, Sebring and ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2BlueInGreen Brings Water Treatment Technology to Florida 2
... Technologies, Inc. (NYSE AMEX: SNT ) announced ... for on-demand viewing. LINK:    www.retailinvestorconferences.com ... button. Senesco Technologies, presentation will be available ... from the "virtual trade booth" for the next three ...
... announced today that Wayne R. Gombotz, Ph.D. has joined ...  Dr. Gombotz brings a significant amount of product ... Immune Design.  He will oversee product development and ... (Logo: http://photos.prnewswire.com/prnh/20111018/SF88252LOGO ) ...
... Dec. 2, 2011 Northwest Biotherapeutics (OTC.BB: NWBO) (Northwest ... clean-up of its balance sheet, removing $31.5 million of ... http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) This ... the end of the third quarter to $16.5 million. ...
Cached Biology Technology:Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer 2Northwest Bio Implements Major Balance Sheet Clean-Up 2Northwest Bio Implements Major Balance Sheet Clean-Up 3Northwest Bio Implements Major Balance Sheet Clean-Up 4Northwest Bio Implements Major Balance Sheet Clean-Up 5
(Date:7/27/2015)... ANGELES , July 27, 2015   ... evidence- and experience-based clinical improvement solutions, today announced ... solution is now available on Android smartphones and ... inpatient and post-care organizations can use ZynxCarebook to ... same patient,s condition, streamline care transitions to other ...
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... new series of article-chapters to be published in the ... better access the wealth of research knowledge obtained on ... function. The series will be authored by top geneticists ... aspects of modern yeast research and its applications to ...
... can deform the shapes of their ears in a way that ... a second, these bats are able to change their outer ear ... , associate professor of mechanical engineering at Virginia Tech. ... is appearing this week in Physical Review Letters ...
... older mice a lower glycemic index (GI) diet consisting ... retinal lesions, according to a new study from the ... Mayer USDA Human Nutrition Research Center on Aging (USDA ... middle-aged and older mice that consumed either a higher ...
Cached Biology News:YeastBook, the Eukaryotic Cell Encyclopedia is launched by Genetics 2Bats show ability to change their ear shapes, making their hearing more flexible 2Bats show ability to change their ear shapes, making their hearing more flexible 3AMD-like lesions delayed in mice fed lower glycemic index diet 2AMD-like lesions delayed in mice fed lower glycemic index diet 3
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Selenoprotein P Purified Anti-Mouse clone 35, Isotype Mouse IgG 2b , 50 µg Consult technical datasheet for details....
Biology Products: